Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.
about
Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gammaDrugs from nature targeting inflammation (DNTI): a successful Austrian interdisciplinary network projectOmega-3 fatty acids for the treatment of non-alcoholic fatty liver diseaseGenetically modified mouse models for the study of nonalcoholic fatty liver diseaseCurcumin suppresses PPARdelta expression and related genes in HT-29 cellsLipid modulatory activities of Cichorium glandulosum Boiss et Huet are mediated by multiple components within hepatocytes.Steatosis and steatohepatitis: complex disorders.The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease.New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Revisiting PPARγ as a target for the treatment of metabolic disordersThe flavonoid, naringenin, decreases adipose tissue mass and attenuates ovariectomy-associated metabolic disturbances in mice.SLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver.Generation and characterization of a humanized PPARδ mouse modelLPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds.Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin SignalingPPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs.Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity.Molecular Interactions between NAFLD and Xenobiotic Metabolism.Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospectiveSignal transduction mechanism of TRB3 in rats with non-alcoholic fatty liver diseaseRegulation of bile acid and cholesterol metabolism by PPARsLiver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression.PPARγ signaling and metabolism: the good, the bad and the future.Iron metabolism in Nonalcoholic Fatty Liver Disease.Role of microRNAs in the regulation of drug metabolism and disposition genes in diabetes and liver disease.Pharmacological agents for NASH.Steatosis in the liver.Carnosic acid (CA) prevents lipid accumulation in hepatocytes through the EGFR/MAPK pathway.The potential of flavonoids in the treatment of non-alcoholic fatty liver disease.Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells.Inflammatory stress exacerbates hepatic cholesterol accumulation via disrupting cellular cholesterol export.The effect of oncoprotein v-erbA on thyroid hormone-regulated genes in hepatocytes and their potential role in hepatocellular carcinoma.IκB kinase-beta inhibitor attenuates hepatic fibrosis in mice.The role of expression imbalance between adipose synthesis and storage mediated by PPAR-γ/FSP27 in the formation of insulin resistance in catch up growth.Update on pparγ and nonalcoholic Fatty liver disease.Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine- and choline-deficient diet.Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease.Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
P2860
Q24567657-3E71F497-1722-4772-90D4-226B87476AC1Q26749192-C0D0E50F-0084-43C9-9F16-BA54B3F4219EQ26825517-99F67655-2679-4BA3-A80C-5145C1D3ECF8Q26865248-7C71E212-698F-4DA6-ABD1-FF4FC5312E2EQ33419214-0AC4007D-4E1D-4977-AB48-4BA8FE77A989Q33569937-B8F51042-A9C8-4166-A792-1227544FDC13Q33907632-7F0C924D-F36A-4F15-AF61-3B22017082A0Q34019843-E24A1E05-9882-424A-B75B-4DD6C9996FB7Q34398065-947D2CE5-3BD6-4B6E-AAC4-E7707B54253FQ34798213-D38BCEEE-180B-45CB-9F24-E53A3BF0F623Q35149393-07148B0A-629A-4FCE-9E4D-295F7AB5796CQ35198043-2C64E84D-07E3-48A7-8646-E9C38026D6E2Q35210055-1E5C90CD-9AF9-48C6-8F4D-7DFF04E3FD0CQ35415945-B4F1A15A-1A46-4888-9EA4-5CC5EC133713Q35903361-D2B96FF9-4818-437D-8062-D8729F9E44AFQ36209797-7C6568CA-A356-4361-A571-6AD6AC29EAABQ36253614-04BB074E-4C41-405D-B546-FDEEEFC22E58Q36293397-E3FD848B-69B2-44E3-B38E-02927F19E90EQ36478196-91C469E5-FF71-42AB-8FB6-8BDE3AC7A95CQ36549795-6446F550-C58B-401F-B7C2-440ED5F6D1C2Q36814812-D312259A-AA69-455B-A50F-A21B182750D1Q37198294-CFA47CB2-8935-4861-898C-81515042451DQ37266779-E7D8D8A7-247B-406E-8CF0-4A6533A2FE51Q37398932-B5EE44C6-81CF-48C6-A0E3-A3497B4BC7F9Q37407887-7874C047-9C3D-46B5-8B0C-2CE5034D123CQ37962398-F1D8392D-7393-4643-A704-CB98F14CD359Q38097092-EE11EDFB-168E-4BC2-85EF-64820650CA7AQ38152646-4602ACC4-31BE-442A-B1FE-FB627C6AB4B8Q38165140-1D334155-779F-458B-A22F-A6FBA8CDBA26Q38327569-425A1438-DD98-45C5-9268-70E97B47DA59Q38432731-3DCCF8D7-18F4-4CF8-9C33-5666EE7DE788Q39208263-6CD84153-DEC4-44B4-9CB1-F8185C926EE5Q39440693-C5C3780B-A39B-4E06-A6EC-9A46A0165431Q39689207-D3A69B69-8028-4356-8794-D4B7C1ABB346Q39945162-03CB8415-97CE-4460-AD98-DC3B42B9E3B2Q41328688-3D02B1E2-8A70-4EBC-9F0E-74BA8D81EDD9Q41903480-44295AE5-79AE-4B05-B142-D4A2E867F304Q41942220-C444E63D-4E0F-4958-B64E-7F89B1E1E6C3Q42569810-9054102E-703D-4E6E-94DF-86FE0D287316Q43294210-1CD0D8EB-7440-4201-8AFE-14D257968048
P2860
Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of peroxisome proliferato ...... alcoholic fatty liver disease.
@en
Role of peroxisome proliferato ...... alcoholic fatty liver disease.
@nl
type
label
Role of peroxisome proliferato ...... alcoholic fatty liver disease.
@en
Role of peroxisome proliferato ...... alcoholic fatty liver disease.
@nl
prefLabel
Role of peroxisome proliferato ...... alcoholic fatty liver disease.
@en
Role of peroxisome proliferato ...... alcoholic fatty liver disease.
@nl
P2860
P356
P1476
Role of peroxisome proliferato ...... nalcoholic fatty liver disease
@en
P2093
Eric R Kallwitz
Scott J Cotler
P2860
P356
10.3748/WJG.14.22
P407
P50
P577
2008-01-01T00:00:00Z